Lundquist Institute Investigator Dr. Eric Daar and Research Team Find That HIV Patients Benefit from Ingestible Sensor Technology on HIV Treatment
Retrieved on:
Tuesday, November 15, 2022
UCLA School of Dentistry, Population health, LOS, Harvard University, Monitoring, Information technology, David Geffen School of Medicine at UCLA, Harbor–UCLA Medical Center, Mental health, Yale University, ARV, Patient, Edible, Media contacts database, HIV-AIDS, HIV Medicine, UCLA, Lundquist, Research, Management of HIV/AIDS, Record, Institute of Health and Biomedical Innovation, Division, Nebraska Medicine, HIV, National Institute of Mental Health, OIP Sensor Systems, HIV/AIDS, Pharmaceutical industry, Medical device, Dentistry, Medicine
The findings Ingestible Sensor System for Measuring, Monitoring and Enhancing Adherence to Antiretroviral Therapy: An Open-label, Usual Carecontrolled, Randomized Trial were published on November 11 in The Lancet Ebiomedicine.
Key Points:
- The findings Ingestible Sensor System for Measuring, Monitoring and Enhancing Adherence to Antiretroviral Therapy: An Open-label, Usual Carecontrolled, Randomized Trial were published on November 11 in The Lancet Ebiomedicine.
- The team of researchers included investigators from UCLA, Nebraska Medical Center, Yale University, and Harvard University.
- When ingested, it is sensed by a patchwith an embedded monitor and sensor that isworn by the patient.
- Our study delivered especially promising results for those who have significant challenges in adhering to antiretroviral medications.